97073 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans Apolipopeptides
METHOD FOR LOADING DIMERIC CD24 INTO HEK293 CELL EXTRACELLULAR VESICLES WITH ADAM10 GENE KNOCKED OUT
#2METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS
#3MODIFIED APOLIPOPROTEINS WITH A TARGETING BODY FOR LIPID NANOPARTICLES
#4APOLIPOPROTEIN NANODISCS WITH TELODENDRIMER
#5PEPTIDES FOR BETA-CELL SURVIVAL AND INSULIN PRODUCTION
#6METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND THE PREVENTION OF ALZHEIMERS DISEASE
#7PEPTIDE USED FOR IMMUNOTHERAPEUTICS
#8LINEAR NUCLEIC ACID EXPRESSION CONSTRUCTS
#9NUCLEIC ACID CONSTRUCT FOR ACHIEVING MODULAR LOADING OF ENGINEERED EVS FUNCTIONAL PROTEIN AND USE OF SAID CONSTRUCT
#10NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES
#11BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES
#12APOE LIPOPROTEIN SYSTEMS
#13USE OF APOLIPOPROTEIN H IN MANUFACTURE OF MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF FATTY LIVER DISEASE AND RELATED DISEASES
#14CER-001 THERAPY FOR TREATING KIDNEY DISEASE
#15LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF
#16COMPOSITION OF MRNA-ENCODED IL15 FUSION PROTEINS AND METHODS OF USE THEREOF
#17PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS
#18GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER’S DISEASE
#19STABLE NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS
#20POLYNUCLEOTIDES ENCODING APOA-1 FUSION POLYPEPTIDES
#21COMPOSITIONS AND METHODS FOR TREATMENT OF PSORIASIS
#22C-TERMINAL FRAGMENT OF APOLIPOPROTEIN E AND APPLICATION THEREOF IN INHIBITING y-SECRETASE ACTIVITY
#23Reconstituted HDL Formulation
#24RECOMBINANT CLUSTERIN AND USE THEREOF IN THE TREATMENT AND PREVENTION OF DISEASE
#25COMPOSITIONS AND METHODS FOR SOLUBILIZING GLYCOSYLTRANSFERASES
#26SYNTHETIC AMPHIPATHIC HELICAL PEPTIDES AND TREATMENT METHODS USING SYNTHETIC AMPHIPATHIC HELICAL PEPTIDES
#27LIPID MEDIATOR CHAPERONE AND USES THEREOF
#28COMPOSITIONS AND METHODS FOR PURIFICATION AND DETECTION OF HDL AND APOAI
#29METHOD FOR PROMOTING PROLIFERATION OF IMMUNE CELLS
#30APOLIPOPROTEIN FUSION PROTEINS FOR CELL-SPECIFIC IMMUNE REGULATION
#31GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE TREM2 P.R47H AND METHODS OF USE THEREOF
#32SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE
#33APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF
#34APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF
#35BARRIER FUNCTION PRESERVING PEPTIDES FOR MEMBRANES
#36PEPTIDE USED FOR IMMUNOTHERAPEUTICS
#37NOVEL ENGINEERED T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
#38MODULATING APOLIPOPROTEIN (A) EXPRESSION
#39MUTATED ARYLSULFATASE A WITH INCREASED STABILITY
#40SYNTHETIC NUCLEIC ACIDS INCLUDING ASTROCYTE-DIRECTED PROMOTER CONSTRUCTS AND METHODS OF USING THE SAME
#41METHOD TO ENHANCE THE EFFICIENCY OF SYSTEMIC AAV GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM
#42COMPOSITIONS AND METHODS FOR TREATMENT OF RHEUMATOID ARTHRITIS AND ACCELERATED ATHEROSCLEROSIS
#43APOMERS
#44APOLIPOPROTEIN B (APOB) POLYPEPTIDES FOR BLOCKING ENDOTHELIAL CELL UPTAKE OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS
#45NANOLIPOPROTEIN-POLYPEPTIDE CONJUGATES AND COMPOSITIONS, SYSTEMS, AND METHODS USING SAME
#46PEPTIDES FOR BETA-CELL SURVIVAL AND INSULIN PRODUCTION
#47CER-001 THERAPY FOR TREATING KIDNEY DISEASE
#48Method for separation and/or detection and/or in vitro quantification of infectious compounds in biological material
#49Lipoprotein complexes and manufacturing and uses thereof
#50Ligand regulated protein-protein interaction system
#51APOLIPOPROTEIN NANODISCS WITH TELODENDRIMER
#52COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE
#53GENE THERAPY FOR ALZHEIMER'S DISEASE
#54PEPTIDE-BASED DELIVERY OF AGENTS
#55GENE THERAPY
#56MODIFIED HEXOSAMINIDASE AND USES THEREOF
#57Lipoprotein complexes and manufacturing and uses thereof
#58A FUSION PROTEIN
#59PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS
#60Fusion protein and use thereof in base editing
#61Reconstituted HDL formulation
#62Peptide used for immunotherapeutics
#63NANOPARTICLES ENCAPSULATING SMALL MOLECULES
#64APOE GENE THERAPY
#65POLYNUCLEOTIDES ENCODING APOA1-RNASE FUSION POLYPEPTIDES
#66NANODISC-SPECIFIC ANTIGEN-BINDING CHIMERIC PROTEINS
#67Base editing tool and use thereof
#68Optimized promoter sequences, intron-free expression constructs and methods of use
#69LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF
#70METHOD OF TARGETING NEURONAL APOE TO TREAT A NEUROCOGNITIVE DISORDER
#71Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
#72HUMAN APOB100 EPITOPES, METHODS AND USES FOR MODULATING INFLAMMATORY RESPONSES, AND TREATING ADVERSE CARDIOVASCULAR EVENTS, DISEASE AND ATHEROSCLEROSIS
#73APOLIPOPROTEIN E FRAGMENTS
#74APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF
#75MULTI-EPITOPIC CONSTRUCT
#76METHODS OF PROTEIN PURIFICATION
#77Polynucleotides encoding APOA1-PON1 fusion polypeptides
#78FUSION PROTEIN AND HIGH-DENSITY LIPOPROTEIN MEASUREMENT KIT USING SAME
#79RECOMBINANT CLUSTERIN AND USE THEREOF IN THE TREATMENT AND PREVENTION OF DISEASE
#80Method and kit for the detection of pancreatic dysfunction
#81GENE THERAPIES FOR NEURODEGENERATIVE DISEASE
#82ANTI-TAU CONSTRUCTS
#83Peptide compounds for suppressing inflammation
#84APOM-FC FUSION PROTEINS FOR TREATING LUNG DISEASES
#85Compositions and methods for purification and detection of HDL and APOAI
#86Heterologous targeting peptide grafted AAVs
#87ApoC-II mimetic peptides
#88CER-001 therapy for treating kidney disease
#89SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS
#90Apolipoprotein nanodiscs with telodendrimer
#91Targeted modification of rat genome
#92Method for treating kidney disorders
#93Bacterial strain for releasing a recombinant protein in a fermentation method
#94Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
#95MANUFACTURING METHOD OF NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN AND NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN MANUFACTURED BY THE SAME
#96Methods for treatment of psoriasis with an anti-Apo B100 antibody
#97GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE
#98Peptides having reduced toxicity that stimulate cholesterol efflux
#99Contaminant removal method
#100APOMERS
#101Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof
#102TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS
#103Engineered T cell receptors and immune therapy using the same
#104LONG-ACTING PROTEIN CONJUGATES FOR BRAIN TARGETING, A PREPARATION METHOD THEREOF, AND A COMPOSITION COMPRISING THE SAME
#105APOM-FC FUSION PROTEINS AND USES THEREOF
#106COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE
#107Reconstituted HDL formulation
#108Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
#109Ligand regulated protein-protein interaction system
#110Modulating apolipoprotein (a) expression
#111Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target
#112Human β2-glycoprotein I expression
#113Drug delivery vehicles for atherosclerosis nanomedicine
#114Therapeutic compositions
#115NANOBIOLOGIC COMPOSITIONS FOR PROMOTING TRAINED IMMUNITY
#116Polynucleotides encoding anti-ApoC3 antibodies
#117Process for preparing apolipoprotein A-I (Apo A-I)
#118Anti-ApoC3 antibodies
#119Engineered T cell receptors and immune therapy using the same
#120ANTI-TAU CONSTRUCTS
#121Anti-ApoC3 antibodies and methods of use thereof
#122ApoC-II mimetic peptides
#123Recombinant clusterin and use thereof in the treatment and prevention of disease
#124Methods for treatment of nephrotic syndrome and related conditions
#125TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS
#126Human APOB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis
#127Genetically modified mouse expressing human APOE4 and mouse Trem2 p.R47H and methods of use thereof
#128Gene therapy
#129Heterologous targeting peptide grafted AAVS
#130Targeted modification of rat genome
#131Peptide-Mediated Non-Covalent Delivery of Active Agents Across the Blood-Brain Barrier
#132Lipoprotein complexes and manufacturing and uses thereof
#133Therapeutic compositions
#134Compositions and methods for purification and detection of HDL and ApoA1
#135Compositions for the administration of APOA1 and dosages
#136Anti-ApoC3 antibodies and methods of use thereof
#137Methods and compositions relating to covalently circularized nanodiscs
#138Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
#139Protein stabilizing factors
#140IMMUNOGENS, COMPOSITIONS, AND METHODS FOR TREATING DYSLIPIDEMIA
#141Peptide compounds for suppressing inflammation
#142METHODS AND VECTORS FOR TREATING CNS DISORDERS
#143ApoM-Fc fusion proteins, complexes thereof with sphingosine 1-phosphate (S1P), and methods for treating vascular and non-vascular diseases
#144COMPOSITIONS AND METHODS OF MODULATING ABETA PROTEIN
#145Stable nanolipoprotein particles and related compositions methods and systems
#146Engineered T cell receptors and immune therapy using the same
#147Anti-APOC3 antibodies and compositions thereof
#148Contaminant removal method
#149Methods and systems for producing nanolipoprotein particles
#150Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Alzheimer's Disease
#151Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
#152Detection apparatus for differential-charged particle mobility analyzer
#153Reconstructed HDL formulation
#154Synthesis and structure of high potency RNA therapeutics
#155Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
#156Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using Apo A-I Milano gene transfer
#157Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
#158PEPTIDE-MEDIATED DELIVERY OF IMMUNOGLOBULINS ACROSS THE BLOOD-BRAIN BARRIER
#159Nanoparticle formulations for delivery of nucleic acid complexes
#160Process for preparing Apolipoprotein A-I (Apo A-I)
#161Peptides having reduced toxicity that stimulate cholesterol efflux
#162LIPOPLEXES FORMULATED FOR CATALYTIC DELIVERY
#163Multi-epitopic construct
#164Heterologous targeting peptide grafted AAVS
#165Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
#166APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS
#167Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
#168RECOMBINANT LIPOPROTEIN MODIFIED BY MONOSIALOTETRAHEXOSYL GANGLIOSIDE AND APPLICATION THEREOF
#169ULTRA-SMALL APOB-CONTAINING PARTICLES AND METHODS OF USE THEREOF
#170Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
#171Thermostable vaccines based on ether lipids and native viral envelope proteins
#172Apolipoprotein nanodiscs with telodendrimer
#173APOBEC3A CYTIDINE DEAMINASE INDUCED RNA EDITING
#174Method and kit for the detection of pancreatic dysfunction
#175Cytophilic peptide-fused high-density lipoprotein, and delivery of drug to posterior segment of eye by ocular installation of said fusion
#176Class of therapeutic protein based molecules
#177Chloroplast Expressing Colostrum or Milk Polypeptides
#178Therapeutic compositions
#179METHOD TO CONCENTRATE APOA-1 MIMETIC PEPTIDES TRANSGENICALLY EXPRESSED IN PLANTS
#180PEPTIDES FOR SUPPRESSING INFLAMMATION
#181ApoE mimetic peptides and higher potency to clear plasma cholesterol
#182Targeted modification of rat genome
#183Use of HDL-related molecules to treat and prevent proinflammatory conditions
#184Charged lipoprotein complexes and their uses
#185Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
#186MODULATING DISEASE THROUGH GENETIC ENGINEERING OF PLANTS
#187Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier
#188Muteins of human lipocalin 2 (Lcn2,hNGAL) with affinity for a given target
#189Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
#190Protein biomarkers for immune assessment and prediction of transplant rejection
#191Substrates and methods for collection, stabilization and elution of biomolecules
#192Production of Therapeutic Proteins in Photosynthetic Organisms
#193Colostrum/milk protein compositions
#194Methods for treatment of nephrotic syndrome and related conditions
#195METHODS AND APPARATUS FOR CREATING PARTICLE DERIVATIVES OF HDL WITH REDUCED LIPID CONTENT
#196Apolipoprotein A-I mimics
#197Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging
#198Polymer conjugate
#199Biochemical markers for CVD risk assessment
#200Chloroplast expressing colostrum or milk polypeptides
#201Cells expressing apolipoprotein E and uses thereof
#202Detection apparatus for differential-charged particle mobility analyzer
#203Peptide compounds for suppressing inflammation
#204METHODS OF TREATING ALZHEIMER'S DISEASE WITH APO A-1 MILANO
#205Cation and anion exchange chromatography method
#206Ultra-small apoB-containing particles and methods of use thereof
#207Recombinant clusterin and use thereof in the treatment and prevention of disease
#208Class of therapeutic protein based molecules
#209Contaminant removal method
#210Process for preparing apolipoprotein A-I (Apo A-I)
#211Myonectin (CTRP15), compositions comprising same, and methods of use
#212Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
#213Apolipoprotein E polypeptides and their use
#214ApoE peptide dimers and uses thereof
#215Lipoprotein complexes and manufacturing and uses thereof
#216Therapeutic compositions
#217CONJUGATES FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE COMPOUNDS
#218Peptides having reduced toxicity that stimulate cholesterol efflux
#219Oxidant resistant apolipoprotein A-1 and mimetic peptides
#220Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging
#221ApoE peptide dimers and uses thereof
#222APOLIPOPROTEIN MIMETICS AND USES THEREOF
#223APOLIPOPROTEIN A-I DERIVED PEPTIDES FOR TREATMENT OF HYPERGLYCAEMIA
#224Compositions and methods for purification and detection of HDL and ApoA1
#225Protein stabilizing factors
#226ON-COLUMN REFOLDING AND PURIFYING OF LIPOPROTEINS
#227Reconstituted HDL formulation
#228MODIFIED APOL1 POLYPEPTIDES
#229Mimetic peptides
#230Apolipoprotein AIV as an antidiabetic peptide
#231Peptides for suppressing inflammation
#232METHOD FOR PRODUCING A LIPID PARTICLE, THE LIPID PARTICLE ITSELF AND ITS USE
#233METHODS OF TREATING ALZHEIMER'S DISEASE WITH APO A-1 MILANO
#234METHODS AND COMPOSITIONS FOR TREATING AMYLOID DEPOSITS
#235Method of treating hyperglycemic disorders using apolipoprotein AIV
#236Nanodisc clathrates and uses thereof
#237Method of treating type I diabetes using apolipoprotein A-IV
#238Lipoprotein complexes and manufacturing and uses thereof
#239Apolipoprotein mixtures
#240IDENTIFICATION OF SPECIFIC APOLIPOPROTEIN EPITOPES ON CIRCULATING ATHEROGENIC LOW-DENSITY LIPOPROTEIN
#241Apolipoprotein A-I mimics
#242Alkaline feed
#243Ultra-small ApoB-containing particles and methods of use thereof
#244Transgenic mouse expressing human apo(a) and human apo(B-100) with disabled vitamin C gene produces human Lp(a)
#245METHOD FOR REDUCTION OF 1->3 READING FRAME SHIFTS
#246Method for reduction of 1->2 reading frame shifts
#247ON-COLUMN ENZYMATIC CLEAVAGE
#248Use of SAA1B/B homozygote in the prognosis and diagnosis of liver cirrhosis
#249Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs
#250Netrin loop peptide mimetics and uses thereof
#251Method of treating diabetes using non-glycosylated apolipoprotein A-IV
#252Shortened tetranectin-apolipoprotein A-1 fusion protein, a lipid particle containing it, and uses thereof
#253METHOD FOR PRODUCING APOLIPOPROTEIN IN PLANTS
#254Myonectin (CTRP15), compositions comprising same, and methods of use
#255Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier
#256Class of therapeutic protein based molecules
#257Use of HDL-related molecules to treat and prevent proinflammatory conditions
#258Methods of regulating angiogenesis by administering agents which increase apoB-100 polypeptide
#259Therapeutic compositions
#260Methods for treating kidney disease with fragments of ApoB-100
#261Peptides having reduced toxicity that stimulate cholesterol efflux
#262Peptide derivatives and use thereof as carriers for molecules in the form of conjugates
#263Reconstituted HDL formulation
#264LRP1 as key receptor for the transfer of sterified cholesterol from very-low-density lipoproteins (VLDL) to ischaemic cardiac muscle
#265CHEMICAL MODIFICATION OF APOLIPOPROTEIN MIMETIC PEPTIDES FOR THE PRODUCTION OF THERAPEUTIC AGENTS
#266Lipoprotein complexes and manufacturing and uses thereof
#267Charged lipoprotein complexes and their uses
#268Methods for treatment of nephrotic syndrome and related conditions
#269Apolipoprotein E polypeptides and their use
#270PEGYLATED HUMAN HDL PARTICLE AND PROCESS FOR PRODUCTION THEREOF
#271Manufacturing and purification processes of Complex protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins
#272TRPM-2 antisense therapy
#273Methods for purification of alpha-1-antitrypsin and apolipoprotein A-1
#274Compositions and methods for treatment of gynecologic cancers
#275Oxidant resistant apolipoprotein A-1 and mimetic peptides
#276APOE IMMUNOTHERAPY
#277Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
#278Peptides for suppressing inflammation
#279FUSION PROTEINS COMPRISING ANTIGENIC APOB-100 PROTEIN FRAGMENTS AND A PROTEIN CARRIER, RELATED COMPOSITIONS, METHODS AND SYSTEMS FOR TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS
#280Apolipoprotein AIV as an antidiabetic peptide
#281Modulating disease through genetic engineering of plants
#282Class of therapeutic protein based molecules
#283P28GANK monoclonal antibody and peptides for preparation thereof and use thereof
#284Serum Amyloid A (SAA) Overrides Regulatory T Cells (TREG) Anergy
#285Anti-trypanosomal peptides and uses thereof
#286Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis
#287Methods for treating steatotic disease
#288Compositions and methods for treating antiphospholipid syndrome
#289Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein A-I and a mutant thereof
#290METHOD FOR THE ISOLATION OF HIGH DENSITY LIPOPROTEIN
#291Apolipoprotein A-I mimics
#292Shortened tetranectin-apolipoprotein A-I fusion protein, a lipid particle containing it, and uses thereof
#293Immunomodulatory methods and systems for treatment and/or prevention of hypertension
#294COMPOSITIONS AND METHODS FOR TREATMENT OF GYNECOLOGIC CANCERS
#295Polymer von Willebrand factor-conjugates
#296Apolipoprotein nanodiscs with telodendrimer
#297Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
#298Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
#299Peptide epitopes of apolipoprotein B
#300Peptide epitopes of apolipoprotein B